Cax

The speaker repeatedly uses the qualifier 'hypothetically' when stating peptide dosages (SS-31 at 2 mg/day, MOTS-c at 1 mg/day, Cax at 400 mcg/day), framing the recommendations as hypothetical for a 'kangaroo' rather than direct human prescriptions. This appears to be a legal disclaimer strategy. The dosages are nonetheless presented with specificity and clinical intent within the context of a burnout recovery protocol.

The speaker provides a specific expected timeline for Cax's effect on dopaminergic system recovery, stating that the 'choice gap' — the ability to pause between stimulus and response indicating restored prefrontal cortex and dopamine function — should return within approximately two weeks on the protocol. If the patient is still reactive and running on fumes at two weeks, the speaker suggests the protocol needs tweaking. This is framed as a subjective but clinically meaningful biomarker of neurochemical recovery.

The speaker issues a direct warning against stacking too many compounds simultaneously, including peptides, citing the example of patients taking 14+ supplements including 'a whole bunch of peptides.' He argues this creates metabolic chaos, overloads the liver and kidneys, and adds additional processing burden to already-failing mitochondria. The warning is framed as a safety and efficacy concern: more compounds do not equal more optimization and can actively worsen the underlying mitochondrial failure being treated.

The speaker presents a comprehensive multi-compound protocol targeting each biochemical mechanism of burnout: SS-31 (2 mg/day) and MOTS-c (1 mg/day) for mitochondrial repair; NAD+ (50 mg/day) for electron transport and DNA repair enzyme activation; CoQ10 (200 mg/day) and PQQ (20 mg/day) for electron carrier substrate and biogenesis signaling; L-Tyrosine (3 g/day) as dopamine/norepinephrine precursor; Cax (400 mcg/day morning) for BDNF-mediated dopaminergic recovery; Magnesium Bisglycinate (500 mg before bed) as NMDA antagonist; and L-Theanine (200 mg before bed) for GABA promotion and glutamate excitotoxicity reduction. The speaker states this protocol takes 20–30 days.

The speaker makes a specific safety and mechanistic distinction that 'Cax' does not act as a dopamine releaser or amphetamine-like stimulant, contrasting it with Adderall, Ritalin, and energy drinks that force dopamine output and deplete reserves. This is framed as a critical differentiator for burned-out patients whose dopamine synthesis enzymes and BH4 cofactors are already depleted. Using a stimulant in this state worsens the underlying biochemical deficit, whereas Cax works through a restorative BDNF pathway.

The speaker recommends a compound referred to as 'Cax,' clarifying it is not a dopamine releaser or amphetamine and does not force output. It is described as working through BDNF (Brain-Derived Neurotrophic Factor) signaling to grow new neuronal connections and recover the dopaminergic system. A dosage of 400 micrograms every day in the morning is specified. The speaker emphasizes it restores dopamine system integrity without forcing depletion of existing stores.

The speaker discloses that he owns Elite Biogenics, the company from which he sources the compounds discussed in the protocol including peptides. He states the company has its own labs and warehouses and that he personally trusts the products enough to give to his family. This is a relevant conflict-of-interest disclosure for evaluating the objectivity of the peptide recommendations made throughout the video.